Stocks · News reference

HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target

Aug 18, 2026, 10:33 AMBenzinga Newsdesk

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $50 price target.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 18, 2026, 10:33 AM
Checked: Aug 18, 2026, 10:33 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 8, 2026, 8:17 PMBenzinga Newsdesk
Assembly Biosciences Says Assembly Bio Eligible For Up To $280M In Milestones And Royalties Outside U.S.; GS-1179 Expected To Advance Into Phase 2 Trial For Genital Herpes By End Of 2026; Assembly Bio Expects Cash Runway Into 2029
ASMB GILD
BenzingaSep 8, 2026, 8:01 PMBenzinga Newsdesk
Assembly Biosciences Announces Exercise Of Option To Share 40% Of U.S. Development Costs And Profits For Gilead-Partnered HSV Helicase-Primase Inhibitor Program In Recurrent Genital Herpes
ASMB GILD
BenzingaSep 1, 2026, 2:49 PMBenzinga Newsdesk
Mizuho Maintains Outperform on Assembly Biosciences, Lowers Price Target to $45
ASMB